CurrentUnitedHealthcarePolicy N/A

Vecamyl (mecamylamine) prior authorization

Prior authorization and reauthorization criteria for Vecamyl (mecamylamine) for management of moderately severe to severe essential hypertension and uncomplicated malignant hypertension for UnitedHealthcare members.

Policy Summary

PayerUnitedHealthcare

PolicyVecamyl (mecamylamine) prior authorization

Policy CodePolicy N/A

Change TypeNo material change

Effective DateDec 1, 2025

Next Review DateOct 1, 2025

Key ActionObtain prior authorization for Vecamyl; initial approvals require a diagnosis of moderately severe to severe essential hypertension or uncomplicated malignant hypertension.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization period

Vecamylmedication

Prior Auth/Notificationprogram type

12/1/2025policy effective

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Reauthorization

Reauthorization will be approved when the following criterion is met:

Reauthorization criterion: Documentation of a positive clinical response to Vecamyl therapy.

Authorization will be issued for 12 months.

Coverage criteria may be affected by applicable laws and the member’s specific benefit plan. State mandates, any federal regulatory requirements, and the member-specific benefit plan coverage may impact whether an individual request meets the policy criteria. Additionally, other UnitedHealthcare policies and utilization management programs may apply and influence coverage decisions.

Provider Actions and Prior Authorization Procedures

Prior Authorization

Prior Authorization Required

Prior authorization is required for Vecamyl. Initial approvals are granted when the member has a diagnosis of moderately severe to severe essential hypertension or uncomplicated malignant hypertension.

Authorization period: 12 months

Note

Automated or Claims-based Approval May Be Used

UnitedHealthcare may use automated approval or approve based on previous claim/medication history, diagnosis codes (ICD-10), and/or claim logic. Use of automated approval and re-approval processes varies by program and therapeutic class.

Documentation Required

Documentation Requirement for Reauthorization

Documentation of a positive clinical response to Vecamyl therapy is required for reauthorization. Reauthorizations will be issued for 12 months when this documentation is provided.

Denial Risk

Claim Denial Risk

Claims that do not document a diagnosis of moderately severe to severe essential hypertension or uncomplicated malignant hypertension, or that lack required reauthorization documentation, may be denied. State mandates, federal requirements, and the member-specific benefit plan may also affect coverage.

Background

Vecamyl (mecamylamine) is indicated for the management of moderately severe to severe essential hypertension and uncomplicated malignant hypertension. Prior authorization is required; initial approvals are granted when the member has one of the covered diagnoses, and authorizations are issued for 12 months. For continuation, reauthorization is granted when there is documentation of a positive clinical response to Vecamyl therapy, and reauthorizations are also issued for 12 months.

Definitions

Vecamyl (mecamylamine) — summary definition

Brand nameVecamyl

Generic namemecamylamine

Indication summaryManagement of moderately severe to severe essential hypertension and uncomplicated malignant hypertension

Drug classAntihypertensive agent

Regulatory/history noteOriginally marketed in the 1950s (brand name Inversine), withdrawn in 2009 (not for safety reasons), and re‑approved by the FDA for U.S. marketing in March 2013.

Rule	Description
Automated approval processes
UnitedHealthcare may approve initial and reauthorization requests based solely on prior claim/medication history, diagnosis codes (ICD-10), and/or claim logic; use of automated approval and re-approval processes varies by program and/or therapeutic class.